← Back to Search

Radiation

APBI: 30 Gy for Breast Cancer (OPAR Trial)

Phase 2

Waitlist Available

Led By Do-Hoon Kim, MD

Research Sponsored by Ontario Clinical Oncology Group (OCOG)

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up ongoing throughout study up to 5 years

Awards & highlights

OPAR Trial Summary

This trial is testing a new type of radiation therapy for breast cancer patients who have had surgery to remove the tumor. The new therapy is called 3DCRT APBI and the patients will be randomly assigned to one of two doses of radiation. The trial will follow the patients for 5 years to see how effective the new therapy is.

Eligible Conditions

Breast Cancer
Ductal Carcinoma

OPAR Trial Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ ongoing throughout study up to 5 years

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~ongoing throughout study up to 5 years

This trial's timeline: 3 weeks for screening, Varies for treatment, and ongoing throughout study up to 5 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Adverse cosmetic outcome using the EORTC Breast Cosmetic Rating System

Secondary outcome measures

Cosmetic deterioration (defined as any adverse change in the global cosmetic score)

Disease free survival (DFS)

Ipsilateral breast tumour recurrence (IBTR)

+2 more

OPAR Trial Design

2Treatment groups

Experimental Treatment

Group I: APBI: 30 GyExperimental Treatment1 Intervention

Radiotherapy of 3 Dimensional Conformal Radiation Therapy (3DCRT) Accelerated Partial Breast Irradiation (APBI) 30 Gy in 5 daily fractions of 6 Gy

Group II: APBI: 27.5 GyExperimental Treatment1 Intervention

Radiotherapy of 3 Dimensional Conformal Radiation Therapy (3DCRT) Accelerated Partial Breast Irradiation (APBI) 27.5 Gy in 5 daily fractions of 5.5 Gy

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

APBI: 27.5 Gy

2016

Completed Phase 2

~280

APBI: 30 Gy

2016

Completed Phase 2

~280

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

Canadian Breast Cancer FoundationOTHER

25 Previous Clinical Trials

8,003 Total Patients Enrolled

14 Trials studying Breast Cancer

6,473 Patients Enrolled for Breast Cancer

Ontario Clinical Oncology Group (OCOG)Lead Sponsor

62 Previous Clinical Trials

41,605 Total Patients Enrolled

15 Trials studying Breast Cancer

8,838 Patients Enrolled for Breast Cancer

Do-Hoon Kim, MDPrincipal InvestigatorJuravinski Cancer Centre

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is it still possible to join this medical trial as a participant?

"In accordance with the clinicaltrials.gov database, this investigation is not currently enrolling participants. The trial was first listed on May 1st 2016 and last edited April 4th 2022. Unfortunately there are no current openings for this particular medical research project; however 2600 other trials have active recruitment periods open at present."

Answered by AI

What is the scope of this research project in terms of its geographic presence?

"Presently, this medical trial is running out of 10 hospitals and research centres. The list includes Barrie, Hamilton, and Quebec City in addition to 7 other cities. To reduce travel commitments it would be prudent to select the location that's closest to you should you decide to join the study."

Answered by AI